ABBV-932 for Generalized Anxiety Disorder
(MAD Trial)
Recruiting at 4 trial locations
AC
Overseen ByABBVIE CALL CENTER
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: AbbVie
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial tests a new medication called ABBV-932 to see how it works in the body and if it is safe for healthy adults and those with anxiety or bipolar disorder.
Research Team
AI
ABBVIE INC.
Principal Investigator
AbbVie
Eligibility Criteria
This trial is for healthy adults, and patients with Generalized Anxiety Disorder (GAD) or Schizophrenia (SCZ), aged 18-65 with a BMI of 18.0 to 32.0 kg/m2. GAD patients must have moderate anxiety and be mildly ill at minimum. Exclusions include recent significant illness, hospitalization, surgery, major depression in the past 3 months, other psychiatric disorders besides GAD and MDD, or substance abuse within the last six months.Inclusion Criteria
Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal.
I am between 18 and 65 years old.
I am 18-65 with GAD, have moderate anxiety, and am at least mildly ill.
Exclusion Criteria
You have had a significant problem with drugs or alcohol in the past 6 months.
You have a history of certain mental health disorders, except for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
I haven't had any serious illnesses, infections, fevers, hospital stays, or surgeries in the last 30 days.
See 1 more
Treatment Details
Interventions
- ABBV-932 (Other)
- Placebo for ABBV-932 (Other)
Trial OverviewThe study tests ABBV-932 against a placebo to see how the body processes it and its safety profile when given multiple times orally to healthy individuals as well as those with GAD or SCZ.
Participant Groups
8Treatment groups
Experimental Treatment
Group I: Part D, Placebo for ABBV-932Experimental Treatment1 Intervention
Participants will receive placebo for ABBV-932 QD for 42 days.
Group II: Part D, ABBV-932Experimental Treatment1 Intervention
Participants will receive ABBV-932 QD for 42 days.
Group III: Part C, Placebo for ABBV-932Experimental Treatment1 Intervention
Participants will receive placebo for ABBV-932 QD for 28 days.
Group IV: Part C, ABBV-932Experimental Treatment1 Intervention
Participants will receive ABBV-932 QD for 28 days.
Group V: Part B, Placebo for ABBV-932Experimental Treatment1 Intervention
Participants will receive placebo for ABBV-932 QD for 28 days.
Group VI: Part B, ABBV-932Experimental Treatment1 Intervention
Participants will receive ABBV-932 QD for 28 days.
Group VII: Part A, Placebo for ABBV-932Experimental Treatment1 Intervention
Participants will receive placebo for ABBV-932 QD for 14 days.
Group VIII: Part A, ABBV-932Experimental Treatment1 Intervention
Participants will receive ABBV-932 once daily (QD) for 14 days.
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois